Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded capsule containing azathioprine, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing azathioprine are listed in tablet and injection forms. No finished azathioprine product of any kind is listed in capsule form.
This is a solid, nonaqueous dose form. Under USP <795>, nonaqueous preparations carry longer default beyond-use dates than water-containing ones. The date printed on the label is the one to follow.
Azathioprine is an immunosuppressant (purine antimetabolite) taken by mouth that pharmacies may compound, including as an oral suspension, on a prescriber's order.
Azathioprine is an immunosuppressant in the thiopurine class. The body converts it to mercaptopurine and then to thioguanine nucleotides, which are built into DNA and slow the growth and activation of immune cells (lymphocytes). Manufactured products include Imuran and Azasan tablets, generic azathioprine tablets, and azathioprine sodium for injection. The Imuran label lists two uses: as an add-on to prevent rejection after kidney transplant, and to reduce signs and symptoms of active rheumatoid arthritis. No commercial liquid form exists, and a stability study in the International Journal of Pharmaceutical Compounding examined compounded azathioprine oral suspensions. A prescriber might order azathioprine compounded as a liquid or in a strength or form that is not manufactured. Compounded preparations are not FDA-approved and require a prescription.
Imuran carries a boxed warning for malignancy: long-term immunosuppression raises cancer risk, including lymphoma after transplant and hepatosplenic T-cell lymphoma in people with inflammatory bowel disease. It can cause severe drops in blood cells, so regular blood counts are needed; people with low TPMT or NUDT15 enzyme activity face a higher risk. Serious infections can occur, and sun exposure should be limited because of skin cancer risk. Allopurinol or febuxostat can raise azathioprine to toxic levels; ACE inhibitors, co-trimoxazole and ribavirin can worsen low blood counts; azathioprine may weaken warfarin. Do not use it if you are allergic to it, or for rheumatoid arthritis during pregnancy; people with rheumatoid arthritis previously treated with alkylating drugs such as cyclophosphamide may face a prohibitive cancer risk. The label says it can cause fetal harm and is not recommended while nursing; LactMed reports low or unmeasurable levels in milk and says many experts consider it acceptable during breastfeeding. Report unusual bleeding, bruising or fever right away. For other side effects, talk to your prescriber or pharmacist.
Azathioprine is metabolized to 6-mercaptopurine (6-MP), which is activated through HGPRT to 6-thioguanine nucleotides (6-TGN); incorporation of 6-TGN into DNA contributes to cytotoxicity. 6-MP is inactivated by TPMT (to 6-MeMP) and xanthine oxidase (to 6-thiouric acid), and NUDT15 converts 6-TGNs to inactive monophosphates. Oral bioavailability is variable (StatPearls); azathioprine and 6-MP are about 30% protein bound, and clinical effect tracks tissue thiopurine nucleotide levels rather than plasma levels. Labeled indications (Imuran tablets): adjunct for prevention of rejection in renal homotransplantation, and active rheumatoid arthritis; the label does not recommend combined use with other DMARDs. The label contraindicates use for rheumatoid arthritis in pregnant women and warns of prohibitive malignancy risk in RA patients previously treated with alkylating agents. StatPearls describes use in autoimmune hepatitis, SLE, ANCA-associated vasculitis and inflammatory myopathies, which are not FDA-approved indications. Prescribers have ordered compounded azathioprine oral suspension; a 2023 IJPC study reported physical, chemical and microbiological stability of such suspensions under refrigerated and room-temperature storage. Dosing is per prescriber; the label advises alternative therapy in homozygous TPMT or NUDT15 deficiency, reduced dosing in heterozygous deficiency, dose reduction with allopurinol, and avoiding febuxostat. Monitor CBC with platelets weekly in the first month, twice monthly in months two and three, then monthly; StatPearls adds baseline liver and renal tests, hepatitis B and C and tuberculosis screening, and TPMT/NUDT15 testing.
Swallow each capsule whole with a glass of water, unless your label says otherwise. Do not crush, chew or open the capsule unless your pharmacist tells you it is safe to do so. Take it at the times shown on your prescription label. If you miss a dose or are unsure how to take it, call the pharmacy.
Capsules are nonaqueous, so under USP <795> they usually carry a beyond-use date of up to 180 days when no other stability data apply. Keep the vial tightly closed at room temperature, away from heat, moisture and direct light, and out of reach of children. Discard any capsules left after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
